BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
POMPANO BEACH, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading medtech company specializing in the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, announced today that it will release its second quarter 2024 financial results after the market close on Monday, August 12, 2024. The company will also host a conference call and webcast at 4:30 PM ET to discuss the results.
Related news for (BSEM)
- BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
- BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
- BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
- BioStem Technologies to Sponsor MRO Better Half Dash